Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2014-02-26 AGM Information
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT annonce la tenue d’une Assemblée Générale Mixte le 2 avril 2014
AGM Information Classification · 98% confidence The document is a press release titled "GENFIT ANNONCE LA TENUE D'UNE ASSEMBLEE GENERALE MIXTE LE 2 AVRIL 2014" (GENFIT ANNOUNCES THE HOLDING OF A COMBINED GENERAL MEETING ON APRIL 2, 2014). It explicitly announces the date, time, and location of the upcoming General Meeting and mentions that the official notice containing the agenda and resolutions is published in the BALO and available online. Since the document's primary purpose is to announce the meeting and the availability of related documentation, it falls under the category for AGM-related announcements. Given the options, AGM-R (AGM Information) is the most appropriate fit, as it covers presentations and materials shared during the AGM, and this announcement precedes the event itself.
2014-02-26 French
GENFIT to hold a Combined General Shareholders’ Meeting on April 2, 2014
AGM Information Classification · 98% confidence The document explicitly announces that GENFIT will hold a 'Combined General Shareholders' Meeting ("the Meeting") on April 2, 2014'. It details the date, time, and location of the meeting, and mentions that the agenda and resolutions are contained in the announcement published in the BALO. This content directly relates to the preparation and scheduling of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document is not the actual voting results (DVA) or the proxy materials (PSI), but the announcement of the meeting itself.
2014-02-26 English
La FDA accorde la désignation ‘Fast Track’ pour le GFT505 dans la NASH
Regulatory Filings Classification · 95% confidence The document is titled 'Communiqué de Presse Press Release' and announces a specific regulatory event: the FDA granting 'Fast Track' designation to the drug GFT505 for NASH treatment. This is a specific, time-sensitive announcement regarding regulatory interaction and drug development progress, not a comprehensive financial report (like 10-K or IR) or a general shareholder communication (like DEF 14A or AGM-R). Since it is a press release announcing a regulatory milestone, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal announcement to the market about regulatory status, which is often disseminated via RNS in European contexts, or it could be considered a general announcement not covered by the more specific financial/governance codes. Given the options, RNS serves as the best fit for a general regulatory/corporate announcement that isn't a core financial report or management change.
2014-02-17 French
The FDA grants Fast Track designation to GFT505 in NASH
Regulatory Filings Classification · 95% confidence The document is a press release dated February 17, 2014, announcing that the FDA granted Fast Track designation to the company's drug candidate GFT505 for NASH treatment. It discusses clinical trial progress (Phase IIb) and future milestones. This type of announcement, detailing a specific regulatory event or clinical update outside of routine financial reporting (like earnings or annual reports), fits best under a general regulatory or corporate update category. Since it is not a formal financial report (10-K, IR, ER), nor a management change (MANG), nor a shareholder vote result (DVA), nor a specific legal filing (LTR), it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format announcing a regulatory milestone, RNS is the most appropriate fallback for a significant, non-standard corporate announcement.
2014-02-17 English
GENFIT : Données pré-cliniques soutenant un mécanisme anti-cancéreux de GFT505.
Regulatory Filings Classification · 92% confidence The document is a press release dated January 29, 2014, announcing new preclinical data for the drug candidate GFT505 showing anti-cancer properties and the filing of a new patent application related to this use. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement of research findings and intellectual property updates. This type of announcement, which details scientific progress and patent activity, fits best under the general category of Investor Information or Regulatory Filings, but given the specific nature of announcing scientific/patent progress, it is often categorized as a general regulatory announcement or a specific type of corporate update. Since there is no specific code for 'Scientific/R&D Update' or 'Patent Filing Announcement', and it is a formal announcement intended for the market, it falls under the broad 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant, non-standard corporate news not covered by other specific codes (like DIV, ER, or MANG). The document length (3731 chars) is short, but it contains the full substance of the news, not just a pointer to another document, so RPA is less appropriate than RNS for substantive news updates.
2014-01-29 French
GENFIT : Preclinical data support anti-cancer effects of GFT505
Regulatory Filings Classification · 90% confidence The document is a press release dated January 29, 2014, announcing new preclinical data regarding the anti-cancer effects of the compound GFT505 and the filing of a new patent application. It details research findings and includes quotes from management. This type of announcement, focusing on research progress, data releases, and patent filings, is typically classified as an Investor Presentation (IP) if it were a formal deck, or more generally, a Regulatory Filing (RNS) if it's a standard press release announcing non-financial operational news that doesn't fit other specific categories like ER, CAP, or LTR. Since it is a general announcement of scientific progress and patent activity, and not a formal financial report (10-K, IR, ER) or a specific legal/management change, RNS (Regulatory Filings - general/miscellaneous) is the most appropriate fallback, although IP could be considered if it were structured more like a presentation summary. Given the format is a news release announcing scientific/patent updates, RNS is the best fit among the provided options for a general corporate update that isn't strictly financial or management-related.
2014-01-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.